

p53-mediated suppression of BiP triggers BIK-induced apoptosis during prolonged endoplasmic reticulum stress

Ignacio López¹, Anne-Sophie Tournillon¹, Rodrigo Prado Martins¹, Konstantinos Karakostis¹, Laurence Malbert-Colas¹, Karin Nylander² and Robin Fähræus^{*,1,2,3}

Physiological and pathological conditions that affect the folding capacity of the endoplasmic reticulum (ER) provoke ER stress and trigger the unfolded protein response (UPR). The UPR aims to either restore the balance between newly synthesized and misfolded proteins or if the damage is severe, to trigger cell death. However, the molecular events underlying the switch between repair and cell death are not well understood. The ER-resident chaperone BiP governs the UPR by sensing misfolded proteins and thereby releasing and activating the three mediators of the UPR: PERK, IRE1 and ATF6. PERK promotes G2 cell cycle arrest and cellular repair by inducing the alternative translated p53 isoform p53 Δ N40 (p53/47), which activates 14-3-3 σ via suppression of p21^{CDKN1A}. Here we show that prolonged ER stress promotes apoptosis via a p53-dependent inhibition of BiP expression. This leads to the release of the pro-apoptotic BH3-only BIK from BiP and activation of apoptosis. Suppression of *bip* mRNA translation is mediated via the specific binding of p53 to the first 346-nt of the *bip* mRNA and via a p53 trans-suppression domain located within the first seven N-terminal amino acids of p53 Δ N40. This work shows how p53 targets BiP to promote apoptosis during severe ER stress and further illustrates how regulation of mRNA translation has a key role in p53-mediated regulation of gene expression during the UPR.

Cell Death and Differentiation (2017) 24, 1717–1729; doi:10.1038/cdd.2017.96; published online 16 June 2017

Stress to the endoplasmic reticulum (ER) impairs the folding capacity of the ER and leads to an accumulation and/or aggregation of misfolded or unfolded proteins which results in the induction of the unfolded protein response (UPR).^{1–3} This condition is observed during both physiological and pathological conditions, such as cancers.

In mammals, the canonical UPR pathway counts on three transmembrane proximal sensors: IRE1, PERK and ATF6.³ IRE1 splices out an intron from the *xbp-1* mRNA which leads to the production of XBP-1 transcription factor.^{4–6} IRE1-dependent RNA decay (RIDD) also degrades a subset of mRNAs coding for proteins trafficking through the ER.^{3,7} PERK phosphorylates the translation initiation factor eIF2 α resulting in general inhibition of cap-dependent translation.⁸ However, some mRNAs encoding proteins required for ER repair, such as ATF4 and p53, are activated by PERK.^{9–11} ATF6 controls the expression of genes with an ER stress response element (ERSE) including chaperones such as the ER-resident BiP (binding immunoglobulin protein or GRP-78 and HSPA5) and notably, *XBP-1*.^{5,12–14} Together, these events aim to restore the balance between newly synthesized and mature proteins.

Extensive ER damage triggers a mitochondria-dependent apoptotic pathway mainly attributed to the activity of CHOP (C/EBP homologous protein, also named GADD153) which is downstream of ATF4.^{3,15} However, PERK or CHOP-deficient

cells still undergo apoptosis during ER stress, indicating the existence of other pro-apoptotic events.^{16,17}

BiP has a key role as a sensor and regulator of the UPR by binding and inhibiting the activity of PERK, IRE1 and ATF6.^{18,19} These associations are disrupted when misfolded proteins accumulate inside the ER.¹³ Expression of BiP requires sustained mRNA translation mediated via regulatory elements present in both the 5' UTR and ORF.^{20–22} BiP represses apoptosis in several cell lines and in mice^{13,23} and this is related with direct and repressive interactions with caspases 7 and 12,²⁴ and with the BH3-only pro-apoptotic member of the BCL-2 family, BIK.^{25,26} In addition, BiP overexpression was described as an adaptive response to stress induced by cancer treatments.¹³

BIK is the founding member of the BH3-only proteins and it exists both as a free cytoplasmic and ER membrane-bound protein.^{27,28} BIK expression is regulated by p53,^{29,30} and controls apoptosis either directly by promoting oligomerisation of BAK and BAX at the ER membrane leading to ER membrane destabilization and Ca²⁺ depletion^{31,32} or indirectly via releasing BAX, but not BAK, from BCL-2 and BCL-XL.^{27,28,33}

p53 regulates the expression of various genes in response to different cellular insults. In response to DNA damage, p53 triggers G1 cell cycle arrest via induction of p21^{CDKN1A} or, if the damage is severe, apoptosis via pro-apoptotic factors




¹Équipe Labellisée Ligue Contre le Cancer, Université Paris 7, INSERM UMR 1162 'Génomique Fonctionnelle des Tumeurs Solides', Paris, France; ²Department of Medical Biosciences; Umeå University, Umeå, Sweden and ³RECAMO, Masaryk Memorial Cancer Institute, Brno, Czech Republic

*Corresponding author: R Fähræus, Équipe Labellisée Ligue Contre le Cancer, Université Paris 7, INSERM UMR 1162 'Génomique Fonctionnelle des Tumeurs Solides', Institut de Génétique Moléculaire, 27 rue Juliette Dodu, Paris 75010, France. Tel: +33142499269; E-mail: robin.fahraeus@inserm.fr

Received 14.11.16; revised 18.4.17; accepted 09.5.17; Edited by J Bartek; published online 16.6.17

such as *Bax*.^{34–37} In the case of ER stress and activation of PERK, the translation initiation of the p53 mRNA switches from the full-length protein (p53FL) to the p53 Δ N40 (p53/47)

isoform. This isoform is initiated at the second in-frame AUG located 40 codon downstream of the first AUG via IRES-dependent mechanisms.^{9,38,39} p53 Δ N40 lacks the first trans-



activation domain (TAD I) of p53 and actively suppresses the expression of $p21^{CDKN1A}$ during ER stress by preventing p53FL-mediated induction of $p21^{CDKN1A}$ transcription and by suppressing $p21^{CDKN1A}$ mRNA translation, which promotes G2 cell cycle arrest.^{9,40} Other studies have implicated p53 in mRNA translation control and to the binding of *mdmx*, *fgf-2*, *cdk4* and its own mRNAs, even though the physiological implications of these events are yet unknown.^{41–45}

Here we set out to better understand the p53 pathway promoting apoptosis during ER stress. We show that prolonged ER stress releases BIK from BiP in a p53-dependent fashion. This requires the suppression of BiP synthesis via a direct interaction between p53 and a small region of the 5' end of the CDS of the *bip* mRNA, in addition to a 7-aa region within the p53 trans-activation domain II (TAD II). These results further emphasize the important role of p53-mediated mRNA translation control during the UPR.

Results

p53 induces apoptosis during ER stress. We first established that p53 induces apoptosis during ER stress by treating cells with different concentrations of thapsigargin (THAP) that prevents Ca^{2+} uptake into the ER from the cytosol.⁴⁶ A low dose of 50 nM THAP for 24 h gave a measurable level of apoptosis using FACS analysis that correlates with detection of apoptotic markers by western blotting (see below). Early and late p53- and ER stress-dependent apoptosis were determined using Annexin-V-FITC and propidium iodide (PI) in H1299 p53-null cells. Thapsigargin treatment alone induced BiP expression but did not generate a significant number of apoptotic cells. However, expression of p53 wild-type (p53wt) (300 ng of cDNA/ 1.75×10^5 seeded cells, 0.15 μ g/ml) in the presence of thapsigargin increased the level of apoptotic cells 1.6-fold as compared with the empty vector (EV)-transfected cells (Figures 1a and b, upper panel).

Induction of apoptosis was further analyzed by detection of caspase-mediated cleavage of PARP-1 using western blotting.⁴⁷ Figure 1b (upper panel) shows an increase in the 89-kDa fragment of PARP-1 (CL-PARP) in H1299 cells transfected with p53wt. A 15-fold increase in CL-PARP was observed in cells treated with thapsigargin and expressing p53wt, as compared with EV-transfected. Similar results were observed in cells treated with tunicamycin (TUN), a drug causing ER stress by inhibiting N-linked glycosylation⁴⁸

(Supplementary Figure 1a). siRNA against p53 in HCT116 p53-positive cells resulted in a 40% reduction in thapsigargin-induced cleavage of PARP-1 (Figure 1b, lower panel). Similar results were obtained using p53-positive A549 cells (Supplementary Figure 1b).

We addressed the kinetics of the induction of apoptosis and Figure 1c shows CL-PARP 24 h post-treatment in the absence of p53. Expression of p53 alone (0 h THAP treatment) was sufficient to detect CL-PARP and the synergistic effect of p53 and ER stress on CL-PARP expression could be observed after 6 h, and longer, of THAP treatment. This indicates that p53 and ER stress together potentiate the induction of apoptosis. ER stress-induced apoptosis is commonly attributed to the activity of CHOP.^{3,15} Interestingly, CHOP expression was detected 3 h post-THAP treatment and peaked at 6 h, before gradually decreasing to non-measurable levels at 24 h. This expression pattern was not affected by p53 (Figure 1c). Even though CHOP levels peaked at 6 h, CL-PARP was not observed before 24 h unless p53 was expressed. When we downregulated CHOP by siRNA, there was only a limited induction of apoptosis in p53-null cells following thapsigargin treatment (Figure 1d). However, cells expressing p53 displayed a 3-fold increase of p53- and ER stress-dependent PARP-1 cleavage in the absence of CHOP, compared with cells transfected with control siRNA and treated with DMSO (Figure 1d).

BiP prevents ER stress- and p53-induced apoptosis. In previous work and during this study, we have observed a small but consistent reduced induction of BiP protein expression ($25\% \pm 10$) following thapsigargin treatment in the presence of p53 (Figure 1b, upper panel).⁴⁰ As BiP has been shown to have an anti-apoptotic effect in both cell lines and in mice,^{13,23} we tested if suppression of BiP induction can help explain p53's capacity to enhance ER stress-induced apoptosis. We first knocked-down BiP using siRNA and observed a 1.4- and 1.7-fold increase in apoptosis in p53-negative (H1299) and p53-positive (HCT116) cell lines treated with 50 nM thapsigargin for 24 h, as determined using FACS analysis (Figure 2a; Supplementary Figures 2a and b). BiP knock-down in DMSO-treated cells did not result in any significant change in apoptosis. Downregulation of BiP induced CL-PARP expression (7- and 2-fold) in thapsigargin-treated H1299 and HCT116 cells, respectively (Figure 2b).

We next tested whether the p53-dependent induction of apoptosis during ER stress depends on BiP expression levels.

Figure 1 p53 induces apoptosis during prolonged ER stress. (a) p53-null non-small cell lung carcinoma H1299 cell line expressing, or not, p53wt were treated with DMSO or 50 nM of thapsigargin (THAP) for 24 h and analyzed for apoptosis by flow cytometry after staining with Annexin V-FITC and propidium iodide (PI). Representative dot plots show the discrimination of viable cells (FITC⁻ PI⁻, Q3), early apoptotic (FITC⁺ PI⁻, Q4) and late apoptotic or necrotic cells (FITC⁺ PI⁺, Q2). The percentage shown on each quadrant represents the number of cells in each group compared with the parent population considered for the analysis. Histogram shows the relative change in percentage of cells in early and late apoptosis/necrosis compared with empty vector (EV)-transfected and DMSO-treated cells, set to 1 (mean \pm S.D., $n = 5$). Two-tailed paired t-test compared data as indicated, $**P < 0.01$. (b) H1299 cells were transfected as indicated. The p53wt colon carcinoma HCT116 cell line was treated, or not, with siRNA against p53. Western blots show the levels of cleaved PARP-1 (85-kDa fragment; CL-PARP) as an apoptotic marker. p53 isoforms were detected by ACMDD serum.^{40,57} BiP was used as a positive control for UPR activation and β -actin as a loading control. Numbers below the blots correspond to relative quantification by densitometry compared with the reference point set to 1. (c) H1299 cells expressing, or not, p53wt were incubated with 50 nM thapsigargin (THAP) at indicated times. Levels of pro-apoptotic CHOP and apoptotic marker CL-PARP were detected by western blotting during indicated time points. Numbers below the blots correspond to relative quantification by densitometry compared with the reference point set to 1. (d) H1299 cells as in Figure 1a were transfected with siRNA targeting CHOP or control siRNA. Downregulation of CHOP was confirmed by western blotting and its effect on apoptosis induction was assessed by detection of CL-PARP. FL-PARP confirmed PARP-1 expression levels are not significantly affected. For all, western blots represent $n \geq 2$




Figure 2 BiP prevents ER stress- and p53-induced apoptosis. (a) p53-null H1299 or p53-proficient HCT116 cells transfected with siRNA against BiP or control siRNA were treated as in Figure 1a and analyzed by FACS. Histograms show the relative change in percentage of cells in early and late apoptosis/necrosis compared with control siRNA-transfected and DMSO-treated cells, set to 1 (mean \pm S.D., $n = 4$). Two-tailed paired *t*-test compared data as indicated, * $P < 0.05$; ns, not significant. (b) H1299 and HCT116 cell lines were transfected or not with siRNA against BiP or control and treated as in Figure 2a. Levels of apoptotic marker CL-PARP and BiP were detected by western blotting. Numbers below the blots correspond to relative expression levels compared with the reference point set to 1. (c) Apoptosis induction was analyzed in H1299 transfected with BiP and/or p53wt, treated and stained with FITC and PI as described in Figure 1a. Histograms show the relative change in percentage of cells in early and late apoptosis/necrosis compared with EV-transfected and DMSO-treated cells, set to 1 (mean \pm S.D., $n = 5$). Two-tailed paired *t*-test compared data as indicated, * $P < 0.05$, ** $P < 0.01$, ns non-significant. (d) Apoptosis induction was estimated by CL-PARP levels in H1299 treated as in Figure 1c. The pro-apoptotic CHOP shows no significant variation. Numbers below the blots correspond to relative quantification by densitometry compared with the reference point set to 1. For all, blots represent $n \geq 2$

Figure 2c (Supplementary Figure 2c) show that BiP expression alone did not change the level of apoptosis under normal conditions or during ER stress. However, the p53-dependent apoptosis observed during prolonged ER stress conditions was counteracted by approximately 50% following BiP overexpression. Importantly, p53-dependent apoptosis in the absence of ER stress was not affected by overexpression of BiP. CL-PARP levels were down by 40% in cells expressing

BiP- and p53wt, as compared with cells expressing p53wt only (Figure 2d).

p53 controls synthesis of BiP. We next investigated what lies behind the observed inverse correlation between p53 and BiP expression. Increasing amounts of exogenous p53wt in cells treated with 50 nM thapsigargin for 24 h, resulted in a dose-dependent downregulation of endogenous BiP




Figure 3 p53 controls BiP protein synthesis. (a) Expression levels of endogenous BiP and exogenous HA-tagged BiP were studied in H1299 cells expressing increasing amounts of p53wt cDNA and treated with 50 nM thapsigargin (THAP) or DMSO for 24 h. HA-BiP expression was differentiated from the endogenous BiP by the use of an antibody against the HA-tag. CM-1 sera was used to detect p53 isoforms. (b) Expression of endogenous *bip* or exogenous *ha-bip* mRNAs were quantified using relative RT-qPCR in H1299 cells transfected or not with p53wt cDNA and treated as in Figure 3a. Values of *bip* and *ha-bip* were normalized against β -actin and GFP, respectively, and are presented as fold change relative to EV-transfected and DMSO-treated cells, set to 1 (mean \pm S.D., $n = 3$ performed in duplicates). Two-way ANOVA compared data of the effect of treatment and transfection of p53wt on *bip* and *ha-bip* mRNAs expression as indicated, $**P < 0.01$; ns, non-significant. (c) De novo BiP protein synthesis. H1299 expressing increasing amounts of p53wt cDNA and incubated with 50 nM thapsigargin (THAP) for 24 h were metabolically pulse labeled with ^{35}S -Met for 20 min in the presence of proteasome inhibitor MG132. Cell extracts were immunoprecipitated (IP) with BiP antibody and levels of IP radiolabelled protein were assessed by autoradiography. Input samples served as control for equal incorporation of ^{35}S -Met into cellular proteins. Western blots show increasing expression of p53 isoforms detected with CM-1 sera. Numbers below the autoradiography correspond to relative quantification compared with the reference point set to 1. Autoradiograph and western blotting shown are representative of $n \geq 2$. (d) *In vitro* translation of *bip* and *gfp* mRNAs in the presence of p53. A recombinant p53 protein was pre-incubated with a mixture of *in vitro*-synthesized *bip* and control *gfp* mRNAs for 15 min at 37 °C before translation was initiated at 30 °C for 1.5 h using rabbit reticulocyte extract in the presence of ^{35}S -Met. Level of radiolabelled proteins were assessed by autoradiography. Autoradiograph shown is representative of $n = 3$

(Figure 3a, upper panel). When we introduced an exogenous HA-tagged BiP construct consisting on the CDS only, we observed a p53 dose-dependent suppression of HA-BiP expression using anti-HA antibody (Figure 3a, lower panel). Using RT-qPCR, we confirmed that neither *bip* nor *ha-bip* mRNA levels were affected by p53 under normal nor ER stress conditions (Figure 3b).

A 20-min pulse with ^{35}S -Met in the presence of the proteasome inhibitor MG132, revealed an $\sim 45\%$ downregulation of BiP synthesis at 0.5 $\mu\text{g}/\text{ml}$ of p53wt cDNA ($1.25 \mu\text{g}/1.75 \times 10^5$ of seeded cells) (Figure 3c). We also evaluated the rate of BiP protein synthesis in an *in vitro* system using a recombinant purified p53 protein (Supplementary Figure 3) together with *in vitro* transcribed capped *bip* and control *gfp*




Figure 4 A p53 mRNA trans-suppressor domain located at aa 40–47. (a) Cartoon representing the p53 isoforms and deletion mutant used to localize the region involved in controlling BiP expression. p53 wild-type (p53wt) cDNA encodes for both p53 full-length (FL) and p53ΔN40 isoforms. p53ΔN40 (also known as p53/47) lacks the first 39 aa of p53FL. p53ΔN47 lacks the first 7 aa of p53ΔN40. TAD; trans-activation domain I and II, PRR; Proline-rich region, DBD; DNA-binding domain, NLS; nuclear localization signal, TET; tetramerization domain, Ct; Carboxi-terminal regulatory domain. (b) p53wt and p53ΔN40 isoforms, but not p53ΔN47, reduce the expression of HA-BiP. H1299 cells expressing different p53 cDNA constructs together with HA-tagged BiP and treated with 50 nM thapsigargin (THAP) or DMSO. (c) Expression of exogenous *ha-bip* mRNAs was quantified using relative RT-qPCR in H1299 cells expressing different p53 cDNA constructs and treated as in Figure 4b. Values of *ha-bip* were normalized against GFP and are presented as fold change relative to EV-transfected and DMSO-treated cells, set to 1 (mean \pm S.D., $n = 3$ performed in duplicates). Two-way ANOVA compared data of the effect of treatment and transfection of p53 on *ha-bip* mRNA expression as indicated, $**P < 0.01$; ns, non-significant. (d) Induction of apoptosis was indirectly determined by analysing the amount of CL-PARP detected by western blotting. Numbers below the blots correspond to relative quantification by densitometry compared with the reference point set to 1. For all, blots represent $n \geq 2$

mRNAs. The mRNAs were pre-incubated with, or without, p53 protein before the *in vitro* translation was performed.⁴⁵ Figure 3d shows that while GFP synthesis was not modified by the presence of p53, the synthesis of BiP was reduced by 70%. Hence, p53's negative effect on *bip* mRNA translation does not require p53-mediated control of gene transcription nor post-translational modifications by UPR pathways.

p53 full-length and p53ΔN40 control BiP expression. We have previously shown that the TAD II domain of p53 has a role in controlling translation of the *mdmx* mRNA.⁴⁵ We therefore decided to test the effect of the natural p53 isoform p53ΔN40 along with different N-terminal deletion mutants on BiP expression, in order to identify a putative p53 domain controlling this activity (Figures 4a and b; Supplementary Figure 4a). p53ΔN40 and p53wt downregulated HA-tagged BiP during both normal and ER stress scenarios, adding to the argument that the capacity to control BiP expression does not require ER stress-dependent activation of p53 (Figure 4b; Supplementary Figure 4a and b). However, deletion of 7 aa (p53ΔN47) adjacent to the initiation site for p53ΔN40, abolished the suppression of HA-BiP (Figure 4b) while deletion of a smaller region (p53ΔN43, Supplementary

Figure 4a) and point mutants (not shown) showed intermediate effects. RT-qPCR confirmed that exogenous *ha-bip* mRNAs levels were not affected by the p53 constructs (Figure 4c).

We then analyzed the effect of these three p53 constructs on apoptosis induction by looking at CL-PARP levels. While expression of p53ΔN47 did not modify the levels of CL-PARP in cells treated with DMSO or with 50 nM thapsigargin for 24 h, p53wt and p53ΔN40 induced CL-PARP both in normal and stress conditions (Figure 4d). These results indicate a direct correlation between p53-mediated trans-suppression of BiP expression and p53-induced apoptosis during ER stress.

p53 binds the coding sequence of *bip* mRNA. We and others have shown that p53 binds to a selected set of mRNAs to control their translation.^{41–45} In order to test if a complex exists between p53 and the endogenous *bip* mRNA *in cellulo*, we used the proximity ligation assay (PLA). A 25 nt DNA oligo corresponding to nt +1010 to +1029 of the *bip* mRNA coupled with digoxigenin at its 3' end was hybridized with the *bip* mRNA on fixed cells. We then used an anti-digoxigenin mouse monoclonal antibody together with CM-1 rabbit anti-p53 sera and detected the *bip* mRNA-p53 protein complexes

in the nucleus and cytoplasm using full-length, p53ΔN40 and p53ΔN47 p53 constructs. The number of complexes detected in the three cases is similar, thus suggesting that the capacity

of p53 to interact with the mRNA is not affected by the N-terminal deletions performed within this study. The CM-1 polyclonal sera detected all three p53 proteins predominantly




Figure 5 p53 binds to the +1 to +346 sequence of the *bip* mRNA. **(a)** Immunofluorescence (IF) of p53 protein (left panels, red signal) and proximity ligation assay (PLA) (right panels, bright yellow dots) between p53 and *bip* mRNA in H1299 cells expressing indicated constructs and treated with 50 nM thapsigargin (THAP) for 24 h. IF and PLA were performed with CM-1 rabbit antibody against p53. For the PLA, a mouse antibody against a digoxigenin-labeled DNA against *bip* mRNA was used together with CM-1. The scale bar corresponds to 10 μ m. Images are representative of $n \geq 10$ cells obtained in two independent experiments. See also Supplementary Figure 5a for PLA controls. **(b)** *In vitro* protein–RNA co-immunoprecipitation shows the specific interaction between p53 and the first 346-nt the 5' coding sequence of the *bip* mRNA. Upper panel shows the different regions of *bip* mRNA that were cloned and used to generate mRNA *in vitro* to assess their capacity to interact with p53. Lower panel shows the quantification of different *bip* mRNAs bound to p53 as determined by RT-qPCR. Data is presented as percentage of RNA bound to p53 and represents the ratio between the RNA bound to p53 and the total RNA (bound+unbound) and normalized to the corresponding no protein control that was set to 100% (mean \pm S.E.M., $n \geq 3$ performed in triplicates). Two-tailed unpaired *t*-test compared data to the corresponding reference point, * $P < 0.05$, ** $P < 0.01$; ns, non-significant

in the nucleus when analyzed by immunofluorescence (IF). As expected, H1299 cells lacking p53 (EV-transfected) were negative for the IF and showed a few PLA dots attributed to experimental background, demonstrating the specificity of the PLA assay (Figure 5a; Supplementary Figure 5a).

We next tested if there is a direct interaction between p53 and the *bip* mRNA. Recombinant purified p53 protein (Supplementary Figure 3) was incubated together with truncated *in vitro*-synthesized *bip* mRNAs before anti-p53 DO1 monoclonal antibody was added. Following immunoprecipitation, the *bip* mRNA bound to p53 and the unbound fractions were quantified by RT-qPCR and the ratio bound/unbound was calculated. This revealed that p53 interacted directly with the full-length CDS of the *bip* mRNA (+1 to +1965) and more specifically to the first 491 nts of the CDS (+1 to +491) (Figure 5b). We further narrowed the interacting region to the +1 to +346 fragment of the CDS (Figure 5b; Supplementary figure 5b). None of the mRNAs lacking the first 346 nts bound to p53.

We then tested if the +1 to +346 *bip* mRNA sequence is sufficient to mediate the interaction with p53 protein *in cellulo*. We generated two reporter constructs where the +1 to +346 or +346 to +1965 sequences of the *bip* mRNA were fused to GFP (*bip*(1-346)-GFP and *bip*(346-1965)-GFP, respectively). These constructs were transfected into H1299 cells together with p53 isoforms (Figure 4a) and their localization was analyzed by IF using a digoxigenin-labeled GFP probe (nt +386 to +413). Figure 6a shows that both reporter mRNAs were similarly expressed and distributed and that their localizations were not modified by the presence of different p53 isoforms. However, PLA using the GFP RNA probe and anti-p53 polyclonal CM-1 sera detected the *bip*(1-346)-GFP in complex with all three p53 proteins in the nucleus and cytoplasm but failed to show the RNA-protein complex using the *bip*(346-1965)-GFP mRNA (Figure 6a). PLA on cells expressing EV were negative for both reporter mRNAs.

A silent *bip*(1-346)-GFP reporter construct (AUGs in the *bip* mRNA segment were mutated to GCG (Ala) codons) was expressed in H1299 cells in the presence of different p53 constructs. This revealed an ~70% and 40% suppression of GFP expression using p53wt and p53ΔN40, respectively, when compared with the EV- or p53ΔN47-transfected cells. The effect on GFP expression alone using the p53 isoforms resulted in an average suppression of 10% (Figure 6b). These results show that the first 346-nt of the *bip* mRNA CDS interact with p53 and are sufficient for p53-mediated mRNA translation control.

p53 induces BIK levels and prevents its interaction with BiP. We next set out to determine the mechanism whereby reduced BiP levels induced cell death. We focused on the BiP-interacting pro-apoptotic protein BIK. The BiP/BIK interaction takes place at the ER membrane and has been suggested to prevent BIK from activating BAX.^{25,26,31,33} We first observed, as reported, that p53wt induces *bik* mRNA levels (Figure 7a).^{29,30} This was observed both under normal and ER stress conditions and, interestingly, the p53ΔN40 and p53wt isoforms induced *Bik* transcription to the same level, an observation that has not been described previously. However, p53ΔN47 did not affect *bik* levels. The *bik* mRNA levels were mirrored by the BIK protein levels (Figure 7b). However, BIK

protein levels were overall suppressed during ER stress, presumably due to the effect of phosphorylated eIF2a.

We next studied the BiP/BIK protein interaction under normal and ER stress conditions. IF indicates that BIK is located in the cytoplasm and that the sub-cellular distribution was not greatly affected by ER stress (Figure 7c). The interaction between BIK and BiP was then assessed by PLA using anti-BIK mouse monoclonal and anti-BiP rabbit polyclonal antibodies. In order to determine the endogenous BIK/BiP complex in cells expressing p53, we carried out a BIK-BiP PLA and at the same time used a p53 antibody (1801) coupled to Alexa Fluor 488. The BiP/BIK complex was detected in the cytoplasm and was, interestingly, not affected by ER stress. This suggests that the basal levels of BiP are sufficient to sequester BIK under non-ER stress conditions when the amount of misfolded proteins in the ER is low. The presence of p53 did not have any effect on the BIK/BiP complex in normal conditions. Interestingly, we observed a sharp decrease in BiP/BIK interactions in cells treated with thapsigargin and expressing p53wt, as shown by the ratio of PLA BIK/BiP complexes in p53-positive/p53-negative cells (1.3 and 0.4 in DMSO and THAP, respectively) (Figure 7d). Importantly, overexpression of increasing amounts of exogenous BiP restored the BiP/BIK interaction in p53wt-expressing and ER-stressed cells (ratio PLA BIK/BiP complexes in p53-positive/p53-negative of 0.8 and 1.0 when 50 and 100 ng of BiP were co-expressed, respectively) (Figure 7d). These data indicate that the levels of BiP expression alone during ER stress determine the interaction with BIK.

Discussion

Solid tumors usually have a constitutive activated UPR and therefore, they are more sensitive to proteasome inhibitors used as cancer drugs, like bortezomib.^{3,49} However, the molecular mechanisms responsible for ER stress-induced apoptosis are still relatively unclear. Like with the DNA damage response pathway, cells strive towards cell cycle arrest and repair following ER stress.^{3,9} However, in the presence of severe DNA damage or ER stress, the cells switch towards pro-death pathways.^{3,16} Both the cell cycle arrest/repair and the pro-apoptotic pathways following these two different damages are partially controlled by p53 but via different mechanisms of action. While p53-dependent control of gene expression during DNA damage relies on transcription, regulation of mRNA translation is favored during the UPR.

ER stress-induced apoptosis has commonly been attributed to CHOP. However, CHOP-deficient cells still undergo apoptosis indicating the existence of additional checkpoints and signaling events mediating cell death.^{16,17} In this study, we observed a synergistic pro-apoptotic effect of prolonged ER stress and p53 that does not appear to involve CHOP. Instead, the p53-mediated induction of apoptosis is linked to a suppression of *bip* mRNA translation and the dissociation of the BIK/BiP complex. It is interesting to notice that even though the suppression of BiP levels by p53 are not too imposing, it is sufficient to completely disperse the BiP/BIK complex. This is presumably related to the fine balance between the interaction between BiP and its ER stress sensors on the one hand and misfolded proteins on the other.




Figure 6 The first 346 nucleotides of the *bip* mRNA coding sequence mediates p53-dependent control of expression. **(a)** IF (p53 olive signal and *bip*-GFP mRNA magenta signal) and PLA (yellow dots) of p53 isoforms and *bip*-GFP mRNA reporter constructs in H1299 cells under normal conditions. IF and PLA were performed with anti-p53 CM-1 rabbit sera and a mouse antibody against a digoxigenin-labeled GFP DNA probe. The scale bar corresponds to 10 μ m. Images are representative of $n \geq 10$ cells obtained in two independent experiments. **(b)** p53 isoform-dependent control of GFP expression from reporter construct *bip*(1-346)-GFP. H1299 expressing either GFP or *bip*(1-346)-GFP (*bip* mRNA lacks in-frame AUG and only expresses GFP) together with indicated p53 constructs. GFP expression was analyzed by western blotting. HSP90 α + β was used as a loading control. Numbers below the blots correspond to relative quantification by densitometry compared with the reference point set to 1. Blot shown is representative of two independent experiments

The BiP/BiK complex has been reported to be at the ER membrane.^{25,26} It is, however, not clear if this interaction is direct, or not, and the proximity assay used here only shows that the complex is disrupted in a p53- and ER stress-dependent fashion. Nevertheless, as the BCL-2/BiK and BiP/BiK complexes are mutually exclusive, it offers an interesting model for how suppression of BiP results in BiK-dependent induction of the apoptotic response.^{25,26}

The suppression of BiP synthesis requires a direct binding between p53 and the 5' of the CDS of the *bip* mRNA. mRNA translation control by p53 has previously been reported but this is the first report that links p53 mRNA binding and translation control to specific cell biological and physiological effects.⁴¹⁻⁴⁵ The lack of apparent sequence homology among the mRNAs implicated as targets for p53 trans-suppression activity add more evidence to the idea that

p53 binding to RNA depends on structure rather than sequence.^{50,51}

The suppression of BiP expression requires a 7-aa trans-suppressor domain of p53 containing an amphipathic α -helical

structure located right after the initiation site of p53 Δ N40 (aa 40–47).^{52,53} This domain was reported to bind replication protein A (RPA)⁵² and the p62 and Tfb1 subunits of human and yeast TFIIH, respectively,⁵³ and it is plausible that the




Figure 7 p53-mediated suppression of BiP dissociates the BIK/BiP complex during prolonged ER stress. (a) Quantification of endogenous *bik* mRNA by relative RT-qPCR. H1299 cells expressing indicated p53 constructs and treated with 50 nM thapsigargin (THAP) or DMSO for 24 h. Values were normalized against β -actin and are presented as fold change relative to EV-transfected and DMSO-treated cells, set to 1 (mean \pm S.D., $n=3$ performed in duplicates). Two-tailed paired *t*-test compared data with the corresponding EV-transfected cells, * $P < 0.05$, ** $P < 0.01$; ns, non-significant. (b) BIK protein levels analyzed by western blotting. Same samples as in Figure 7a were used to detect endogenous BIK protein. Blots represent $n=3$. (c) IF of endogenous BIK (green, Alexa488) and BiP (red, Alexa647) proteins in H1299 cells treated as in Figure 7a. The scale bar corresponds to 10 μ m. Images are representative of $n \geq 10$ cells obtained in two independent experiments. (d) PLA of endogenous BIK and BiP (yellow dots) in H1299 cells expressing increasing amounts of BiP in normal and in ER stress conditions using anti-BIK mouse monoclonal and anti-BiP polyclonal antibodies. BiP(50 ng) and BiP(100 ng) refer to 50 and 100 ng of transfected BiP, respectively. p53 expression was detected by IF using p53 monoclonal antibody 1801 labeled with Alexa Fluor 488. The scale bar corresponds to 10 μ m. Images are representative of $n \geq 10$ cells obtained in three independent experiments. Histogram shows quantification of BIK/BiP PLA complexes as ratio \pm S.D. of PLA dots in p53-expressing divided by dots in p53-negative cells captured as a pair in the same image. 5 images were considered in each case. Two-tailed paired *t*-test compared data to the p53wt-EV-DMSO condition, ** $P < 0.01$; ns, non-significant

trans-suppressive activity of p53 depends on a yet unknown factor binding this domain.

The capacity of p53ΔN40 to induce transcription of *Bik* further adds to the notion that the TAD I (aa 1 to 40) and TAD II (aa 40 to 60) domains of p53 have different cell biological effects under different cellular conditions. The TAD I is associated with the control of G1 cell cycle progression and p53 lacking TAD I are unable to trans-activate *p21^{CDKN1A}*^{40,54,55}. On the other hand, the TAD II impinges on apoptosis-related genes as supported by the induction of *Bax*⁵⁶ and here on *Bik*. In addition, p53ΔN40-dependent induction of *Fas*, *Dr5*, *Api1* and *Pig3* upon exposure to a variety of stress signals also promote apoptosis.⁵⁵

These data suggest a model whereby p53 induces the expression of BIK while at the same time inhibits the induction of BiP and together, this promotes the dissociation of the BIK/BiP complex following ER stress. This sheds light on the pro-apoptotic pathway during prolonged ER stress and offers new therapeutic approaches to sensitize tumor cells suffering from ER stress for apoptosis induction.

Finally, the capacity of p53 to induce G2 cell cycle arrest during the UPR depends on suppression of *p21^{CDKN1A}* mRNA translation.⁴⁰ This, together with the effect described here, strengthens the notion that mRNA translation has a more important role in p53 activity during the ER stress response, as compared with its transcription regulatory activity during the DNA damage response.

Materials and Methods

Cell culture. p53-positive HCT116 (colon carcinoma) and A549 (lung carcinoma) or p53-null H1299 (non-small cell lung carcinoma) and Saos-2 (osteosarcoma) human cell lines were used. HCT116 cells were kindly provided by Professor B. Vogelstein (Johns Hopkins University, Baltimore, MD, USA). Other cell lines were purchased from the American Type Culture Collection (Manassas, VA, USA). H1299 and Saos-2 cells were cultured in RPMI 1640 medium (no glutamine), HCT116 cells in McCoy's 5 A medium (modified, GlutaMAX) and A549 cells in Dulbecco's modified Eagle's medium medium (high glucose, no glutamine). All media (Gibco, Waltham, MA, USA) were supplemented with 10% fetal bovine serum (Gibco), 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco) and 2 mM L-glutamine (Gibco), except for McCoy's 5 A; L-glutamine was not added. Cell lines were maintained at 37 °C in an humidified 5% CO₂ incubator. All experiments were performed using exponentially growing cells and cell counts were carried out using a Malassez hemocytometer.

Cell transfection and treatment. Twenty-four hours before transfection, 1.75×10^5 cells were seeded in each well of a six-well plate for most experiments, 7.5×10^5 cells in 10-cm diameter plates for metabolic pulse labeling and 1.5×10^4 cells in each well of a 24-well plate for Proximity Ligation Assay and Immunofluorescence. cDNA transfections were made using GeneJuice reagent (Millipore, Darmstadt, Germany) following manufacturer's protocol and empty vector was added when needed to keep constant the total amount of transfected DNA. If indicated, after 8 h, medium was replaced for siRNA transfection. siRNAs targeting BiP, BIK, CHOP or p53 and AllStars negative control siRNA (Qiagen, Valencia, CA, USA) were transfected using HiPerFect reagent (Qiagen) following manufacturer's instructions. Efficiency of siRNAs was assessed by western blot analysis. Cells were further incubated for 24 h before treatment. Cells were treated with 50 nM thapsigargin (THAP, Sigma-Aldrich, St. Louis, MO, USA), 7.5 mg/ml tunicamycin (TUN, Sigma-Aldrich) prepared in DMSO (Euromedex, Strasbourg, France) or 0.1% DMSO (Euromedex) for 24 h unless specified otherwise.

Expression vectors. All constructs were in pcDNA3 (Life Technologies, Carlsbad, CA, USA) unless otherwise indicated. p53wt and p53ΔN40 (p53/47) constructs have been described previously^{9,40} and are schematically represented in Figure 4a. p53wt codes for both p53 full-length (p53FL) and p53ΔN40 isoforms.

Site-directed mutagenesis was performed to clone p53ΔN47 by deleting the aa 2–8 from p53ΔN40. The BiP construct was made by amplifying the BiP's ORF from total mRNA extracted from H1299 cells, retro-transcribed using oligo(dT)₁₂₋₁₈ primer (Life Technologies) and then amplified by PCR using restriction sites-containing primers flanking the ORF of BiP. The HA-BiP plasmid was obtained by PCR amplification from the above-mentioned BiP with the forward primer containing the HA-tag (ATGTACCCATACGATGTTCCAGATTACGCT). The constructs carrying *bip* mRNA segments +1 to +982, +983 to +1965, +1 to +491, +492 to +982 and +1 to +346 were generated by amplification using specific primers and the BiP construct and sub-cloned into pcDNA3 and are schematically represented in Figure 5b. *bip* (1-346)-GFP (+1 to +346 of *bip* mRNA) reporter construct was made as follows: GFP ORF was amplified from pEGFP-N1 vector (Clontech, Mountain View, CA, USA) and was inserted into pcDNA3. The first 346-nt of the above-mentioned BiP construct were amplified and cloned up-stream of GFP's ORF in-frame and subsequently, the in-frame Met codons 1 and 9 of BiP were converted into Ala (GCG) codons by site-directed mutagenesis. *bip*(346-1965)-GFP (+346 to +1965 of *bip* mRNA) was generated by amplification with specific primers from the BiP construct and sub-cloned into pcDNA3 up-stream of GFP as for the previous construct.

Western blotting. Cells were lysed in lysis buffer (20 mM HEPES KOH pH 7.5, 50 mM β-glycerophosphate, 1 mM EDTA pH 8.0, 1 mM EGTA pH 8.0, 0.5 mM Na₃VO₄, 100 mM KCl, 10% glycerol and 1% Triton X-100) supplemented with complete protease inhibitor cocktail (Roche, Basel, Switzerland). Protein concentration was determined using Bradford reagent (Bio-Rad, Hercules, CA, USA) and equal protein amounts were separated by NuPAGE gel electrophoresis (Life technologies). After electrophoretic transfer to BioTrace NT pure nitrocellulose blotting membrane (PALL, NY, USA), membranes were blocked with 5% non-fat dry milk in Tris-buffered saline pH 7.6 containing 0.1% Tween-20. Proteins were probed by overnight (ON) incubation at 4 °C with the following antibodies: Anti-HA-tag mouse monoclonal antibody (mAb), anti-p53 CM-1 and ACMDD rabbit polyclonal antibodies (pAbs) were kindly provided by Dr. B. Vojtesek (Masaryk Memorial Cancer Institute, Brno, Czech Republic). For the ACMDD sera raised against the N-terminus of p53ΔN40, the membranes were pre-incubated with 0.4% paraformaldehyde (PFA) at room temperature for 1 h and washed with water (Gibco) (three times for 5 min) before blocking. Anti-cleaved PARP-1 rabbit pAb was from Cell Signaling Technology (Danvers, MA, USA), anti-BiP rabbit pAb and anti-CHOP mouse mAb were purchased from Abcam (Cambridge, UK), anti-BIK mouse mAb and anti-PARP-1 rabbit pAb were purchased from Santa Cruz (Dallas, TX, USA), anti-β-actin mouse mAbs were purchased from Sigma-Aldrich, anti-GFP mouse mAb was purchased from Roche. Membranes were then incubated with appropriate HRP-conjugated secondary antibodies (Dako, Glostrup, Denmark) and detection was performed using WestDura (Thermo Fisher Scientific, Waltham, MA, USA) and either Hyperfilm (GE Healthcare, Little Chalfont, UK), CHEMI-SMART 5000 documentation system and Chemi-Capt software (Vilbert Lourmat, Eberhardzell, Germany) or myECL Imager and myImage Analysis software (Thermo Fisher Scientific). The two latter were used for protein bands quantification by densitometry analysis performed with either Bio-PROFIL Bio 1D software (Vilbert Lourmat) or ImageJ.

Apoptosis assay. Both floating and attached cells were collected 24 h following DMSO or THAP treatment for HCT116 and H1299. Cells were then simultaneously stained with Annexin V-FITC and PI using the Annexin V-FITC Apoptosis Detection Kit from Sigma-Aldrich, as per manufacturer's instructions. Annexin V binds to exposed phosphatidylserines on early apoptotic cells, whereas the non-vital dye propidium iodide (PI) stains late apoptotic and necrotic cells. Counting of cells was performed for 20 000 events using BD FACSCanto II flow cytometer and analysis was carried out with BD FACSDiva software (BD Biosciences, San Jose, CA, USA).

RNA extraction, reverse transcription and RT-qPCR. Total RNA was extracted with RNeasy Mini Kit (Qiagen) following manufacturer's instructions. cDNA synthesis was carried out using the Moloney murine leukaemia virus reverse transcriptase and Oligo(dT)₁₂₋₁₈ primer (Life technologies). RT-qPCR was performed by the StepOne real-time PCR system (Applied Biosystems, Foster City, CA, USA) using Perfecta SYBR Green FastMix, ROX (Quanta Biosciences, Beverly, MA, USA) and the following primers: BiP-F 5'GCAACCAAGACGCTGGAAC3', BiP-R 5'CCTCCCTCTTATCCAGGCCATA3', HA-BiP-F 5'CCCATACGATGTTCCAGATTA CG3', HA-BiP-R 5'CCACGTCCTCCTTCTGTCT3', BIK-F 5'CCTGCACCTGCT GCTCAAG3', BIK-R 5'ACCTCAGGCGAGTGGTCATG3', EGFP-F 5'CATGCCCGA AGGCTACGTC3', EGFP-R 5'TCAGCTCGATGCGGTTCCACC3', β-Actin-F 5'TCAC

CCCACTGTGCCATCTACGA3' and β -Actin-R 5'TGAGGTAGTCAGTCAGGTC CGG3'.

Metabolic radiolabelling and immunoprecipitation. After seeding, transfection and treatment, cells were kept at 37 °C and 5% CO₂ in Dulbecco's modified Eagle's starvation medium (not including methionine, cystine and L-glutamine, Sigma-Aldrich) supplemented with 2% fetal bovine serum dialysed against PBS (Gibco), 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin, and DMSO or THAP for 1.5 h together with 25 μ M of the proteasome inhibitor MG132 (Calbiochem, San Diego, CA, USA) for the final 50 min. Cells were metabolically radiolabelled with 45 μ Ci/ml of EasyTag Express ³⁵S-methionine Protein Labeling Mix (PerkinElmer, Waltham, MA, USA) during the final 20 min. Cells were lysed in lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl and 1% NP-40) supplemented with complete protease inhibitor cocktail (Roche). Equal protein amounts, as determined by Bradford (Bio-Rad), were pre-cleared with rabbit or mouse serum (Dako) and Dynabeads Protein G (Life Technologies). Samples were immunoprecipitated by overnight incubation with anti-BiP rabbit pAb (Abcam), anti-HA-tag mouse mAb (provided by Dr. B. Vojtesek) or non-specific mouse IgG antibody (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) at 4 °C and beads that were added 2 h after the Abs. Beads were washed and boiled in 2X Laemmli buffer. Proteins were resolved in NuPAGE gel electrophoresis (Life Technologies) fixed in 7% methanol and 20% acetic acid and the signal was amplified by incubation with Amplify (GE Healthcare). Finally, gels were dried. Detection was achieved by exposure to X-ray film. Autoradiography of input samples confirmed equal incorporation of overall ³⁵S-methionine into cellular proteins. For quantification of immunoprecipitated radiolabelled proteins, gels were exposed to phosphor imager screen, scanned using a Storm 840 phosphorimager (Molecular Dynamics, GE Healthcare) and analyzed with Image-Quant software (Molecular Dynamics, GE Healthcare).

In vitro translation. N-terminal His-tagged full-length p53 was cloned into pET-28a (Novagen, Madison, WI, USA) and was expressed in BL21 (DE3) *Escherichia coli*. Lysis was performed with 25 mM Hepes pH 8.0, 100 mM NaCl, 1 mM Tris, 20 mM imidazole, 10% glycerol, 10 μ M ZnSO₄ supplemented with protease inhibitor cocktail EDTA-free (Roche). p53 was then purified with HisTrap HP 1 mL columns (GE Healthcare) and ÄKTApurifier 10 (GE Healthcare) as per manufacturer's instructions. *bip* and *gfp* mRNAs were *in vitro*-synthesized and capped with mMMESSAGE mMACHINE T7 kit (Ambion, Carlsbad, CA, USA) following manufacturer's instructions and using as template the linearized pCDNA3 containing either BiP or GFP sequences (described above). Both *bip* and *gfp* mRNAs (400 ng of each) in the same reaction, along with 0.5 μ M of partially-purified p53 protein were pre-incubated in binding buffer containing 50 mM Tris pH 7.5, 150 mM NaCl, 0.02 μ g/ml yeast tRNA (Ambion), 0.2 mg/ml BSA (Sigma-Aldrich) for 15 min at 37 °C. *In vitro* translation assays were performed with 41 μ Ci/ml of Easytag Express Protein Methionine Mix (PerkinElmer) and Reticulocyte Lysate system (Promega, Madison, WI, USA) according to the manufacturer's protocol for 1.5 h at 30 °C and boiled in 2X Laemmli buffer. Proteins were resolved by NuPAGE gel electrophoresis (Life Technologies), followed by fixation, amplification and drying of the gels. Detection was achieved by exposure to X-ray film (GE Healthcare).

In vitro protein-RNA co-immunoprecipitation. p53-purified protein (see before) was used. In addition to *bip* FL mRNA, segments +1 to +982, +983 to +1965, +1 to +491, +492 to +982 and +1 to +346 were synthesized as described. All binding reactions were carried out for 15 min at 37 °C in binding buffer containing 50 mM Tris pH 7.5, 150 mM NaCl, 0.02 μ g/ml yeast tRNA, 0.2 mg/ml BSA. 120 ng of recombinant p53 protein and a fixed amount (0.01 pmol) of different *bip* mRNAs were used. After incubation, RNA-protein complexes were pulled-down ON at 4 °C using anti-p53 DO-12 mouse mAb kindly provided by Dr. B. Vojtesek and protein G sepharose Fast Flow (Sigma-Aldrich). The unbound fraction was recovered for later analysis and the bound RNA was released from the beads using proteinase K (Sigma-Aldrich) for 30 min at 55 °C. All RNA fractions were then extracted and purified using the TRIzol protocol (Life Technologies). RT-qPCR was performed using primers for the following segments: FL (+1 to +1965), +1 to +982, +492 to +982; same primers used for qPCR, +983 to +1965; F 5'GTCCACAGATTG AAGTACC3' and R 5'CCTGTACCCTTGCTTCAGC3', +1 to +491 and +1 to +346; F 5'CACGCCGCTCTATGTCGC3' and R 5'TGTTCTCGGGGTTGGAGG3', +1 to +246; F 5'GGCCGCGTGGAGATCATC3' and R 5'GGCGCATCGCCAA TCAG3'. The relative binding of each mRNA to proteins was expressed as the ratio of bound to total (bound+free) RNA.

IF and PLA. For IF of proteins, following seeding, transfection and treatment, coverslips with cells were briefly washed with PBS and fixed with 4% PFA for 20 min at RT, washed again with PBS and blocked with blocking buffer (PBS 3% BSA, 0.1% saponin) for 30 min at RT. Primary Abs were diluted in blocking buffer, 1:500 for anti-p53 CM-1 rabbit pAb, 10 μ g/ml for anti-BiP rabbit pAb (Abcam) and 1.5 μ g/ml for anti-BIK mouse mAb (Santa Cruz) and incubated in a wet chamber for 90 min at RT. After several washes with PBS, goat secondary Abs anti-mouse IgG-Alexa488 and anti-rabbit IgG-Alexa647 (Molecular Probes, Life Technologies) diluted 1:500 into blocking buffer were added and incubated in a wet chamber for 45 min at RT. Finally, samples were stained with 50 ng/ml DAPI (Sigma-Aldrich) in PBS for 5 min at RT and washed with PBS at RT before mounting. For the protein-protein PLA, samples were treated as for IF until primary antibody incubation. After that, DuoLink II PLA kit (Sigma-Aldrich) was used following manufacturer's instructions using custom solutions, followed by DAPI staining, washing with PBS and mounting. For the protein-protein PLA coupled to IF against p53, following PLA amplification samples were washed with PLA buffer B for 5 min at RT, incubated with 1:250 dilution of anti-p53-Alexa488 mouse mAb 1801 (Abcam) in blocking buffer for 40 min in wet chamber at RT, stained with DAPI in buffer B for 5 min at RT, washed with buffer B, rinsed with 0.01 \times buffer B and mounted. In protein-RNA PLA or RNA IF, coverslips with cells were briefly washed with PBS and fixed with 4% PFA for 20 min at RT, washed again with PBS and incubated in 70% ethanol for 6 h at 4 °C. Samples were re-hydrated with PBS for 30 min at RT, permeabilized with 0.4% Triton X-100, 0.05% CHAPS in PBS for 5 min at RT, washed with PBS, incubated in hybridization buffer (2 \times SSC, 0.2 mg/ml *E. coli* tRNA (Roche), 0.2 mg/ml sheared salmon sperm DNA (Life Technologies), 2 mg/ml BSA (Sigma-Aldrich)) in a wet chamber for 30 min at RT and hybridized with 50 ng of DNA probe coupled to digoxigenin at its 3' (previously denatured at 80 °C for 5 min) in hybridization buffer in wet chamber ON at 37 °C. Anti-*bip* DNA probe 5'CTG GACGGGCTTCATAGTAGAAAAA3'-DIG and anti-*gfp* DNA probe 5' AGGATGTT GCGCTCCTCTGAAGTCGAAAAA3'-DIG were used (Eurogentec, Liège, Belgium). Samples were briefly washed with wash buffer (2X SSC, 10% formamide), further washed twice with hybridization buffer for 20 min and once with PBS for 20 min at 37 °C, followed by the above-described PLA and IF protocols using 1:200 dilution of anti-digoxigenin mouse mAb (Sigma-Aldrich) and 1:500 for anti-p53 CM-1 rabbit pAb in blocking buffer. Images were obtained either with Axiovert 200M microscopy and AxioVision software (Carl Zeiss Vision, Oberkochen, Germany) or LSM 800 airyscan confocal microscopy and Zen 2.1 (blue edition) software (Carl Zeiss Microscopy GmbH, Oberkochen, Germany). Number of PLA BIK/BiP complexes were quantified using ImageJ in pairs of p53-positive and p53-negative cells and a ratio was calculated.

Statistical analysis. Data shown represent the mean \pm S.D. (unless specified otherwise) of minimum three independent experiments. Two-tailed paired and unpaired Student's *t*-test were performed by comparing data to the corresponding reference point or as indicated and two-way ANOVA was used when different groups of samples were compared. *P*-values are shown on graphs. **P*<0.05; ***P*<0.01; ****P*<0.001; ns, not significant.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements. This work was supported by la Ligue Contre le Cancer, the Inserm and the projects INCA_9413, GACR P206/12/G151 and MEYS-NPS I-L01413. I.L. was supported by AXA Research Fund and Fondation pour la Recherche Médicale FRM (FDT20150532276). A-S.T. was supported by PACRI. R.P. M. was supported by Institut National du Cancer (INCA_10683). K.K. was supported by Institut National du Cancer (INCA_9413). We greatly thank the members of the Plateforme Technologique from the Institut Universitaire d'Hématologie (IUH), Paris, France for their valuable technical assistance.

- Behnke J, Feige MJ, Hendershot LM. BiP and its nucleotide exchange factors Grp170 and Sii1: mechanisms of action and biological functions. *J Mol Biol* 2015; **427**: 1589–1608.
- Morito D, Nagata K. Pathogenic hijacking of ER-associated degradation: is ERAD flexible? *Mol Cell* 2015; **59**: 335–344.
- Hetz C, Chevet E, Harding HP. Targeting the unfolded protein response in disease. *Nat Rev Drug Discov* 2013; **12**: 703–719.
- Calton M, Zeng H, Urano F, Till JH, Hubbard SR, Harding HP *et al*. IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. *Nature* 2002; **415**: 92–96.

5. Lee K, Tirasophon W, Shen X, Michalak M, Prywes R, Okada T *et al.* IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response. *Genes Dev* 2002; **16**: 452–466.
6. Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. *Cell* 2001; **107**: 881–891.
7. Hollien J, Weissman JS. Decay of endoplasmic reticulum-localized mRNAs during the unfolded protein response. *Science* 2006; **313**: 104–107.
8. Jackson RJ, Hellen CU, Pestova TV. The mechanism of eukaryotic translation initiation and principles of its regulation. *Nat Rev Mol Cell Biol* 2010; **11**: 113–127.
9. Bourouga K, Naski N, Boularan C, Mlynarczyk C, Candeias MM, Marullo S *et al.* Endoplasmic reticulum stress induces G2 cell-cycle arrest via mRNA translation of the p53 isoform p53/47. *Mol Cell* 2010; **38**: 78–88.
10. Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M *et al.* Regulated translation initiation controls stress-induced gene expression in mammalian cells. *Mol Cell* 2000; **6**: 1099–1108.
11. Vattem KM, Wek RC. Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. *Proc Natl Acad Sci USA* 2004; **101**: 11269–11274.
12. Haze K, Yoshida H, Yanagi H, Yura T, Mori K. Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress. *Mol Biol Cell* 1999; **10**: 3787–3799.
13. Lee AS. Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential. *Nat Rev Cancer* 2014; **14**: 263–276.
14. Yoshida H, Haze K, Yanagi H, Yura T, Mori K. Identification of the cis-acting endoplasmic reticulum stress response element responsible for transcriptional induction of mammalian glucose-regulated proteins. Involvement of basic leucine zipper transcription factors. *J Biol Chem* 1998; **273**: 33741–33749.
15. Oyadomari S, Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. *Cell Death Differ* 2004; **11**: 381–389.
16. Urra H, Dufey E, Lisbona F, Rojas-Rivera D, Hetz C. When ER stress reaches a dead end. *Biochim Biophys Acta* 2013; **1833**: 3507–3517.
17. Zinszner H, Kuroda M, Wang X, Batchvarova N, Lightfoot RT, Remotti H *et al.* CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. *Genes Dev* 1998; **12**: 982–995.
18. Bertolotti A, Zhang Y, Hendershot LM, Harding HP, Ron D. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. *Nat Cell Biol* 2000; **2**: 326–332.
19. Shen J, Chen X, Hendershot L, Prywes R. ER stress regulation of ATF6 localization by dissociation of BiP/GRP78 binding and unmasking of Golgi localization signals. *Dev Cell* 2002; **3**: 99–111.
20. Gulow K, Bienert D, Haas IG. BiP is feed-back regulated by control of protein translation efficiency. *J Cell Sci* 2002; **115**: 2443–2452.
21. Macejak DG, Sarnow P. Internal initiation of translation mediated by the 5' leader of a cellular mRNA. *Nature* 1991; **353**: 90–94.
22. Starck SR, Tsai JC, Chen K, Shodiya M, Wang L, Yahiro K *et al.* Translation from the 5' untranslated region shapes the integrated stress response. *Science* 2016; **351**: aad3867.
23. Luo S, Mao C, Lee B, Lee AS. GRP78/BiP is required for cell proliferation and protecting the inner cell mass from apoptosis during early mouse embryonic development. *Mol Cell Biol* 2006; **26**: 5688–5697.
24. Rao RV, Peel A, Logvinova A, del Rio G, Hermel E, Yokota T *et al.* Coupling endoplasmic reticulum stress to the cell death program: role of the ER chaperone GRP78. *FEBS Lett* 2002; **514**: 122–128.
25. Fu Y, Li J, Lee AS. GRP78/BiP inhibits endoplasmic reticulum BIK and protects human breast cancer cells against estrogen starvation-induced apoptosis. *Cancer Res* 2007; **67**: 3734–3740.
26. Zhou H, Zhang Y, Fu Y, Chan L, Lee AS. Novel mechanism of anti-apoptotic function of 78-kDa glucose-regulated protein (GRP78): endocrine resistance factor in breast cancer, through release of B-cell lymphoma 2 (BCL-2) from BCL-2-interacting killer (BIK). *J Biol Chem* 2011; **286**: 25687–25696.
27. Chinnadurai G, Vijayalingam S, Rashmi R. BIK the founding member of the BH3-only family proteins: mechanisms of cell death and role in cancer and pathogenic processes. *Oncogene* 2008; **27**: S20–S29.
28. Wilfling F, Weber A, Potthoff S, Vogtle FN, Meisinger C, Paschen SA *et al.* BH3-only proteins are tail-anchored in the outer mitochondrial membrane and can initiate the activation of Bax. *Cell Death Differ* 2012; **19**: 1328–1336.
29. Germain M, Mathai JP, Shore GC. BH-3-only BIK functions at the endoplasmic reticulum to stimulate cytochrome c release from mitochondria. *J Biol Chem* 2002; **277**: 18053–18060.
30. Mathai JP, Germain M, Marcellus RC, Shore GC. Induction and endoplasmic reticulum location of BIK/NBK in response to apoptotic signaling by E1A and p53. *Oncogene* 2002; **21**: 2534–2544.
31. Mathai JP, Germain M, Shore GC. BH3-only BIK regulates BAX, BAK-dependent release of Ca²⁺ from endoplasmic reticulum stores and mitochondrial apoptosis during stress-induced cell death. *J Biol Chem* 2005; **280**: 23829–23836.
32. Wang X, Olberding KE, White C, Li C. Bcl-2 proteins regulate ER membrane permeability to luminal proteins during ER stress-induced apoptosis. *Cell Death Differ* 2011; **18**: 38–47.
33. Gillissen B, Essmann F, Hemmati PG, Richter A, Richter A, Oztop I *et al.* Mcl-1 determines the Bax dependency of Nbk/Bik-induced apoptosis. *J Cell Biol* 2007; **179**: 701–715.
34. Chipuk JE, Green DR. Dissecting p53-dependent apoptosis. *Cell Death Differ* 2006; **13**: 994–1002.
35. el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J *et al.* WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. *Cancer Res* 1994; **54**: 1169–1174.
36. Krackova M, Akiri G, George A, Sachidanandam R, Aaronson SA. A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis. *Cell Death Differ* 2013; **20**: 576–588.
37. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. *Cell* 1995; **80**: 293–299.
38. Candeias MM, Powell DJ, Roubalova E, Apcher S, Bourouga K, Vojtesek B *et al.* Expression of p53 and p53/47 are controlled by alternative mechanisms of messenger RNA translation initiation. *Oncogene* 2006; **25**: 6936–6947.
39. Ray PS, Grover R, Das S. Two internal ribosome entry sites mediate the translation of p53 isoforms. *EMBO Rep* 2006; **7**: 404–410.
40. Mlynarczyk C, Fahraeus R. Endoplasmic reticulum stress sensitizes cells to DNA damage-induced apoptosis through p53-dependent suppression of p21(CDKN1A). *Nat Commun* 2014; **5**: 5067.
41. Galy B, Creancier L, Prado-Lourenco L, Prats AC, Prats H. p53 directs conformational change and translation initiation blockade of human fibroblast growth factor 2 mRNA. *Oncogene* 2001; **20**: 4613–4620.
42. Galy B, Creancier L, Zanibellato C, Prats AC, Prats H. Tumour suppressor p53 inhibits human fibroblast growth factor 2 expression by a post-transcriptional mechanism. *Oncogene* 2001; **20**: 1669–1677.
43. Miller SJ, Suthiphongchai T, Zambetti GP, Ewen ME. p53 binds selectively to the 5' untranslated region of cdk4, an RNA element necessary and sufficient for transforming growth factor beta- and p53-mediated translational inhibition of cdk4. *Mol Cell Biol* 2000; **20**: 8420–8431.
44. Mosner J, Mummembrauer T, Bauer C, Sczakiel G, Grosse F, Deppert W. Negative feedback regulation of wild-type p53 biosynthesis. *EMBO J* 1995; **14**: 4442–4449.
45. Tournillon AS, Lopez I, Malbert-Colas L, Findakly S, Naski N, Olivares-Illana V *et al.* p53 binds the mdmx mRNA and controls its translation. *Oncogene* 2017; **36**: 723–730.
46. Rogers TB, Inesi G, Wade R, Lederer WJ. Use of thapsigargin to study Ca²⁺ homeostasis in cardiac cells. *Biosci Rep* 1995; **15**: 341–349.
47. Chaitanya GV, Steven AJ, Babu PP. PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. *Cell Commun Signal* 2010; **8**: 31.
48. Tkacz JS, Lampen O. Tunicamycin inhibition of polyisoprenyl N-acetylglucosaminyl pyrophosphate formation in calf-liver microsomes. *Biochem Biophys Res Commun* 1975; **65**: 248–257.
49. Mujtaba T, Dou QP. Advances in the understanding of mechanisms and therapeutic use of bortezomib. *Discov Med* 2011; **12**: 471–480.
50. Riley KJ, Cassidy LA, Kumar A, Maher LJ 3rd. Recognition of RNA by the p53 tumor suppressor protein in the yeast three-hybrid system. *RNA* 2006; **12**: 620–630.
51. Riley KJ, Maher LJ 3rd. p53 RNA interactions: new clues in an old mystery. *RNA* 2007; **13**: 1825–1833.
52. Bochkareva E, Kaustov L, Ayed A, Yi GS, Lu Y, Pineda-Lucena A *et al.* Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A. *Proc Natl Acad Sci USA* 2005; **102**: 15412–15417.
53. Di Lello P, Jenkins LM, Jones TN, Nguyen BD, Hara T, Yamaguchi H *et al.* Structure of the Tfb1/p53 complex: Insights into the interaction between the p62/Tfb1 subunit of TFIIF and the activation domain of p53. *Mol Cell* 2006; **22**: 731–740.
54. Ghosh A, Stewart D, Matlashewski G. Regulation of human p53 activity and cell localization by alternative splicing. *Mol Cell Biol* 2004; **24**: 7987–7997.
55. Phang BH, Othman R, Bougeard G, Chia RH, Frebourg T, Tang CL *et al.* Amino-terminal p53 mutations lead to expression of apoptosis proficient p47 and prognosticate better survival, but predispose to tumorigenesis. *Proc Natl Acad Sci USA* 2015; **112**: E6349–E6358.
56. Yin Y, Stephen CW, Luciani MG, Fahraeus R. p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. *Nat Cell Biol* 2002; **4**: 462–467.
57. Lopez I, Tournillon AS, Nylander K, Fahraeus R. p53-mediated control of gene expression via mRNA translation during Endoplasmic Reticulum stress. *Cell Cycle* 2015; **14**: 3373–3378.



This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/4.0/>

© The Author(s) 2017